Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Alnylam Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Alnylam Pharmaceuticals yıllık ortalama 8.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.7% annual. Gelirler yılda ortalama 43.2% oranında büyüyor .

Anahtar bilgiler

8.9%

Kazanç büyüme oranı

11.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	43.2%
Özkaynak getirisi	n/a
Net Marj	-3.1%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23

Gelir ve Gider Dağılımı

Alnylam Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:ALNY Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	2,344	-73	856	1,080
31 Mar 24	2,003	-332	823	1,035
31 Dec 23	1,828	-440	796	1,004
30 Sep 23	1,724	-510	808	994
30 Jun 23	1,237	-1,064	845	987
31 Mar 23	1,143	-1,065	800	944
31 Dec 22	1,037	-1,131	771	883
30 Sep 22	961	-1,182	747	850
30 Jun 22	884	-981	653	799
31 Mar 22	880	-893	628	776
31 Dec 21	844	-853	621	792
30 Sep 21	749	-838	619	713
30 Jun 21	688	-887	662	662
31 Mar 21	571	-876	663	617
31 Dec 20	493	-858	588	655
30 Sep 20	401	-891	646	620
30 Jun 20	345	-846	594	624
31 Mar 20	286	-886	574	637
31 Dec 19	220	-886	534	600
30 Sep 19	169	-821	482	534
30 Jun 19	101	-858	477	515
31 Mar 19	86	-802	446	491
31 Dec 18	75	-761	425	463
30 Sep 18	92	-692	379	454
30 Jun 18	107	-570	306	414
31 Mar 18	93	-525	264	370
31 Dec 17	90	-491	230	360
30 Sep 17	69	-462	191	346
30 Jun 17	66	-443	166	349
31 Mar 17	59	-414	137	342
31 Dec 16	47	-410	119	352
30 Sep 16	37	-388	106	333
30 Jun 16	30	-361	98	305
31 Mar 16	30	-342	93	291
31 Dec 15	41	-290	82	255
30 Sep 15	58	-221	78	229
30 Jun 15	62	-188	71	208
31 Mar 15	61	-160	67	186
31 Dec 14	51	-360	63	172
30 Sep 14	37	-371	56	150
30 Jun 14	35	-357	52	139
31 Mar 14	37	-331	45	119
31 Dec 13	47	-89	41	99

Kaliteli Kazançlar: ALNY şu anda kârlı değil.

Büyüyen Kar Marjı: ALNY şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ALNY kârlı değildir, ancak son 5 yılda zararlarını yılda 8.9% oranında azaltmıştır.

Büyüme Hızlandırma: ALNY 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ALNY kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ALNY 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Alnylam Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Recent updates

Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Price target increased by 8.3% to US$281

Consensus revenue estimates increase by 15%

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

CEO & Director notifies of intention to sell stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024

Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$1.9m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$243

RNAi: Winning In The Clinic, Now For The Market

Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Key Executive notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.52 loss per share (vs US$1.40 loss in 1Q 2023)

Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives

Co-Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 10%

CEO & Director recently sold US$1.0m worth of stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024

Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024

Alnylam's Huge Opportunity

Forecast to breakeven in 2026

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Chief Innovation Officer notifies of intention to sell stock

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Consensus revenue estimates increase by 28%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

No longer forecast to breakeven

Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Consensus EPS estimates fall by 10%

Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Insider notifies of intention to sell stock

CEO & Director recently sold US$1.5m worth of stock

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$5.98 loss, revenue downgraded

President exercised options and sold US$4.7m worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$1.2m worth of stock

Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025